Match!
Nature Reviews Drug Discovery
IF
57.62
Papers
4465
Papers 4485
1 page of 449 pages (4,485 results)
Newest
Published in Nature Reviews Drug Discovery57.62
M. Teresa Villanueva2
Estimated H-index: 2
Published in Nature Reviews Drug Discovery57.62
Asher Mullard23
Estimated H-index: 23
Recursion, Janssen, insitro and others are combining high-content phenotypic screening with machine learning to zoom in on emerging opportunities in target discovery, hit identification, toxicity testing and more. Recursion, Janssen, insitro and others are combining high-content phenotypic screening with machine learning to zoom in on emerging opportunities in target discovery, hit identification, toxicity testing and more.
Published in Nature Reviews Drug Discovery57.62
Simon Faissner9
Estimated H-index: 9
(U of C: University of Calgary),
Jason R. Plemel (U of A: University of Alberta)+ -3 AuthorsV. Wee Yong58
Estimated H-index: 58
(U of C: University of Calgary)
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that involves demyelination and axonal degeneration. Although substantial progress has been made in drug development for relapsing–remitting MS, treatment of the progressive forms of the disease, which are characterized clinically by the accumulation of disability in the absence of relapses, remains unsatisfactory. This unmet clinical need is related to the complexity of the pathophysiological mechanisms invo...
Published in Nature Reviews Drug Discovery57.62
Jorrit Schaefer , Sorcha Cassidy2
Estimated H-index: 2
,
Rachel M. Webster5
Estimated H-index: 5
Published in Nature Reviews Drug Discovery57.62
George S. Baillie49
Estimated H-index: 49
(Glas.: University of Glasgow),
Gonzalo S. Tejeda7
Estimated H-index: 7
(Glas.: University of Glasgow),
Michy P. Kelly6
Estimated H-index: 6
(USC: University of South Carolina)
Phosphodiesterases (PDEs), enzymes that degrade 3′,5′-cyclic nucleotides, are being pursued as therapeutic targets for several diseases, including those affecting the nervous system, the cardiovascular system, fertility, immunity, cancer and metabolism. Clinical development programmes have focused exclusively on catalytic inhibition, which continues to be a strong focus of ongoing drug discovery efforts. However, emerging evidence supports novel strategies to therapeutically target PDE function,...
Published in Nature Reviews Drug Discovery57.62
Asher Mullard23
Estimated H-index: 23
12345678910